Donna Strano
About Donna Strano
Donna Strano is an Enterprise Architect currently working at Bristol-Myers Squibb and Celgene, with extensive experience in IT account management and enterprise architecture.
Current Role at Bristol-Myers Squibb
Donna Strano is presently serving as an Enterprise Architect at Bristol-Myers Squibb. Her work involves developing and implementing enterprise architecture strategies to support the company's objectives. She utilizes her extensive experience in IT account management and enterprise architecture to enhance operational efficiency and effectiveness within the pharmaceutical industry.
Current Role at Celgene
Donna Strano is also working as an Enterprise Architect at Celgene in Summit, New Jersey, United States. In this role, she is responsible for creating and maintaining the enterprise architecture framework that supports Celgene's business strategies and objectives.
Previous Experience at Merck
Donna Strano spent 16 years at Merck in various roles, building substantial expertise in IT account management and enterprise architecture. From 1998 to 2007, she worked as a Program and Project Manager, followed by a four-year tenure as an Architect from 2007 to 2011. She then served as Director of IT Account Management from 2011 to 2014. Throughout her time at Merck, she gained invaluable experience managing large-scale IT projects and programs, significantly contributing to the company's IT infrastructure.
Educational Background
Donna Strano achieved her Master's degree from Fairleigh Dickinson University, enhancing her technical and managerial skills. Prior to that, she completed her Bachelor's degree at Kean University. Her formal education has provided a solid foundation for her career in enterprise architecture and IT management.
Experience in Enterprise Architecture
Donna Strano has been working as an Enterprise Architect since December 2014. Her extensive experience includes developing IT strategies and architectures that align with business goals. She has a robust understanding of the pharmaceutical industry's unique challenges and requirements, which she leverages to drive innovation and efficiency in her current roles.